KemPharm (KMPH) Begins FDRR Process to Appeal FDA Complete Response Letter on Apadaz
Tweet Send to a Friend
KemPharm, Inc. (Nasdaq: KMPH) announced it has appealed the Food and Drug Administration's (FDA) Complete Response Letter (CRL) for Apadaz ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE